Allergan Aesthetics reports skin quality improvements in people taking medical weight loss medications

Allergan Aesthetics, an AbbVie company, has reported findings from two clinical studies evaluating skincare and dermabrasion approaches in people taking medical weight loss medications, including glucagon like peptide 1 receptor agonists.

The results are being presented at the 2026 Science of Skin Summit in Austin, Texas.

Both studies assessed whether targeted skincare regimens, either alone or combined with DiamondGlow dermabrasion, could improve skin quality in areas including the face, neck, upper inner arms and distal thighs.

The first study followed participants for 12 weeks and evaluated a skincare regimen containing a growth factor serum, neck cream and firming and toning body lotion.

Nine participants completed the 12 week study.

Investigators observed statistically significant visible improvements in selected skin quality measures from as early as week two.

These included improvements in dryness, skin tone evenness, crepiness, tactile roughness, lines and wrinkles, and overall skin texture.

A second six week study assessed DiamondGlow treatments used alongside the topical skincare regimen.

Eleven participants completed at least one assessment after treatment.

Improvements in selected skin quality measures were observed immediately following DiamondGlow treatment.

Participants also reported high levels of satisfaction across both studies, although Allergan Aesthetics noted that results varied according to treatment area, regimen, assessment time and the relatively small number of participants.

In the 12 week skincare study, participants reported that their facial skin appeared approximately 10 years younger after four weeks of using the growth factor serum twice daily.

Participants in the six week study reported that their facial skin appeared around 7.5 years younger after receiving three DiamondGlow treatments alongside six weeks of topical skincare.

Elizabeth Makino, Director of Clinical Development and Global Scientific Affairs for Skincare Research and Development at Allergan Aesthetics and a co author of both studies, said medical weight loss therapies are creating increasing interest in changes to skin quality, including firmness, laxity and crepiness.

She said the early findings provide clinical evidence on skincare and non invasive dermabrasion approaches in people using medical weight loss medications.

Makino added that larger studies will be needed to better characterise the results and understand how these approaches could address changing aesthetic needs among patients.

The findings will be presented through two electronic posters during the Science of Skin Summit.

One poster will focus on skin quality improvements associated with a skincare regimen in individuals taking medical weight loss medication.

The second will examine skin quality changes following dermabrasion combined with the skincare regimen.

---

---

Related Topics and Keywords

aesthetics, clinical research, dermabrasion, diamond glow, glp1, medical weight loss, pharma news, skin health, skin quality, skincare